In:
International Journal of Gynecologic Cancer, BMJ, Vol. 33, No. 9 ( 2023-09), p. 1394-1401
Abstract:
MicroRNAs (miRNAs) have emerged as biomarkers that showed strong diagnostic potential in various diseases, including cancer. This study aimed to estimate the expression and diagnostic potential of miRNAs (miR-200a, miR-21, miR-210, miR-126, and miR-130a) in endometrial cancer samples. The DICER1 and AGO2 genes were also analysed. Methods The expression of miRNAs, DICER1, and AGO2 was quantified using the quantitative real-time PCR method in 40 tissue samples with early-stage endometrial cancer and 16 normal controls. Results All tested miRNAs showed significantly higher expression in endometrial cancer compared with the control group, while DICER1 was significantly downregulated. The expression levels of miR-200a, miR-21, and miR-210 were negatively correlated with DICER1 expression. Individually, miR-200a, miR-21, miR-210, and DICER1 showed the best diagnostic performance in distinguishing patients with endometrial cancer from normal controls, whereas a combination of all biomarkers resulted in an even higher area under the curve. Conclusions Our study showed that a panel of selected biomarkers (miR-200a, miR-21, miR-210, miR-126, miR-130a, DICER1, and AGO2) may be candidates for the detection of early-stage endometrial cancer.
Type of Medium:
Online Resource
ISSN:
1048-891X
,
1525-1438
DOI:
10.1136/ijgc-2023-004579
DOI:
10.1136/ijgc-2023-004579.supp1
Language:
English
Publisher:
BMJ
Publication Date:
2023
detail.hit.zdb_id:
2009072-9